Stock 688177 BIO-THERA SOLUTIONS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Bio-Thera Solutions, Ltd. Share Price

Equities

688177

CNE100003R98

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
32.05 CNY +1.97% Intraday chart for Bio-Thera Solutions, Ltd. +12.89% -22.28%
03-25 Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006 CI
03-20 Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company MT

Financials

Sales 2024 * 1.49B 206M 16.47B Sales 2025 * 2.48B 343M 27.45B Capitalization 13.27B 1.83B 147B
Net income 2024 * -22M -3.04M -243M Net income 2025 * 571M 78.8M 6.31B EV / Sales 2024 * 8.91 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 5.34 x
P/E ratio 2024 *
-641 x
P/E ratio 2025 *
23.2 x
Employees 1,167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 20.8%
More Fundamentals * Assessed data

Chart Bio-Thera Solutions, Ltd.

Dynamic Chart

Latest news about Bio-Thera Solutions, Ltd.

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006 CI
Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company MT
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026 CI
Bio-Thera Solutions Gets Regulatory Nod for Trial of Tumor Drug Combination Treatment MT
Bio-Thera Solutions Wins US FDA Nod to Market Cancer Drug MT
FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin CI
Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chugai Parent Roche Settles US Lawsuit Against Biogen Over Alleged Biosimilar Infringement MT
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar MT
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug RE
Bio-Thera Partner Gets US FDA Marketing Nod for Arthritis Injectable MT
FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration CI
More news

Press releases Bio-Thera Solutions, Ltd.

Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor AQ
Recent Biosimilar Approvals AQ
Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S AQ
Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab AQ
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar BU
More press releases

News in other languages on Bio-Thera Solutions, Ltd.

Sandoz pourra distribuer aux USA un biosimilaire chinois de l'Avastin de Roche
Sandoz-Partner erhält US-Zulassung für Biosimilar für Roche-Blockbuster
More news

Quotes and Performance

1 day+1.97%
1 week+12.89%
Current month-10.47%
1 month-13.38%
3 months-7.90%
6 months-7.96%
Current year-22.28%
More quotes

Highs and lows

1 week
28.39
Extreme 28.39
32.40
1 month
27.83
Extreme 27.83
36.47
Current year
24.03
Extreme 24.03
41.92
1 year
24.03
Extreme 24.03
47.46
3 years
17.09
Extreme 17.09
47.46
5 years
17.09
Extreme 17.09
78.00
10 years
17.09
Extreme 17.09
78.00
More quotes

Managers and Directors - Bio-Thera Solutions, Ltd.

Managers TitleAgeSince
Sheng Feng Li CEO
 Chief Executive Officer 65 27/07/03
Xian Hong Zhan DFI
 Director of Finance/CFO 46 18/04/19
Xiao Yun Wu CHM
 Chairman 43 31/12/10
Members of the board TitleAgeSince
Cheuk Kin Law BRD
 Director/Board Member 61 09/09/20
Sheng Feng Li CEO
 Chief Executive Officer 65 27/07/03
Jin Chen Yu BRD
 Director/Board Member 66 31/12/12
More insiders

Quotes

Date Price Change Volume
26/04/24 32.05 +1.97% 1,265,933
25/04/24 31.43 +4.04% 2,440,773
24/04/24 30.21 +1.79% 2,109,205
23/04/24 29.68 +2.34% 2,158,691
22/04/24 29 +2.15% 2,479,885

End-of-day quote Shanghai S.E., April 25, 2024

More quotes

Company Profile

Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.
Sector
Biotechnology & Medical Research
Calendar
22/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
32.05 CNY
Average target price
54 CNY
Spread / Average Target
+68.49%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIO-THERA SOLUTIONS, LTD. Stock Bio-Thera Solutions, Ltd.
-22.28% 1.83B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688177 Stock